JNJ-38877618

JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.

Product Specifications

CAS Number

[943540-74-7]

UNSPSC

12352005

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/JNJ-38877618.html

Concentration

10mM

Purity

98.76

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

FC(C1=CC=C2N=CC=CC2=C1)(F)C3=NN=C4C=CC(C5=CC=NC=C5)=NN43

Molecular Formula

C20H12F2N6

Molecular Weight

374.35

References & Citations

[1]Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA) : AACR; Cancer Res 2018;78 (13 Suppl) :Abstract nr 4791.